Gut Health & GI Repair Peptide Stack 2026: BPC-157, KPV, Larazotide & Pentadecarginate Research Protocol

# Gut Health & GI Repair Peptide Stack 2026: BPC-157, KPV, Larazotide & Pentadecarginate Research Protocol

> Research Disclaimer: This information is for research purposes only (PMID: 40861487). The compounds described in this article are research chemicals not approved for therapeutic use in humans outside of clinical trial settings. This is not medical advice. Consult appropriate medical and regulatory professionals before any research use.

Overview

The intestinal barrier — a single-cell-thick epithelial lining covered by mucus and populated by trillions of microbes — is arguably the most complex interface in the human body. It must simultaneously allow nutrient absorption, maintain immune surveillance, and prevent pathogenic bacteria, toxins, and undigested food particles from entering systemic circulation. Dysfunction of this barrier underlies or exacerbates dozens of conditions: inflammatory bowel disease, celiac disease, irritable bowel syndrome, autoimmune disease, and even neurological and metabolic disorders through the gut-brain and gut-liver axes.

This research protocol examines four peptides that target distinct mechanisms of gut repair and barrier maintenance:

• •BPC-157 (Body Protection Compound 157) — mucosal cytoprotection and healing
• •KPV (Lys-Pro-Val) — anti-inflammatory NF-κB suppression via gut epithelial PepT1
• •Larazotide Acetate (AT-1001) — tight junction integrity via zonulin antagonism
• •Pentadecarginate (PDA) — structural repair and mucosal scaffold support

Each compound addresses a fundamentally different mechanism of gut dysfunction, making this a rationally designed multi-target stack for GI repair research.

Why Stack These Peptides? Mechanistic Rationale

Gut barrier dysfunction is multifactorial: inflammatory cytokines disrupt tight junctions, oxidative stress damages epithelial cells, dysregulated immune signaling perpetuates mucosal inflammation, and structural damage impairs the physical scaffold of the intestinal wall. No single compound addresses all these dimensions:

BPC-157 works primarily through angiogenesis (VEGFR2 upregulation), growth factor modulation (EGF, bFGF), and nitric oxide system regulation to promote mucosal healing and cytoprotection. It is the "frontline healer" in this stack.

KPV is an alpha-MSH-derived tripeptide that acts directly on gut epithelial cells through the PepT1 oligopeptide transporter, suppressing NF-κB-driven inflammation from within the intestinal lining. It targets the inflammatory signaling axis that drives chronic mucosal inflammation.

Larazotide acetate works at the tight junction level, blocking zonulin — the physiological regulator of paracellular permeability — from opening tight junctions. By maintaining ZO-1 and occludin localization at cell junctions, it directly addresses the "leaky gut" phenotype.

Pentadecarginate (PDA) provides structural scaffold support, potentially through arginine-based NO signaling and direct cell membrane stabilization, complementing the healing initiated by BPC-157.

Together, these four compounds form a logical sequence: Larazotide closes the gaps (tight junctions), KPV quells the inflammation driving damage, BPC-157 accelerates mucosal repair and angiogenesis, and PDA supports gut barrier function (PMID: 39397201), the structural recovery of the gut wall.

Compound Profiles

BPC-157 (Body Protection Compound 157)

Molecular weight: 1,419.5 Da

Structure: Phe-Asp-Glu-Phe-His-Asp-Ile-Lys-His-Ala-Ile-Glu-Asp-Arg-Ser-OH (15 amino acids)

Origin: Derived from a region of human gastric juice protein; fully synthetic

BPC-157 is one of the most extensively studied research peptides, with a body of literature spanning over three decades from Predrag Sikiric's laboratory at the University of Zagreb and numerous independent research groups:

Mucosal cytoprotection and healing: BPC-157 demonstrates potent mucosal protective effects in models of aspirin/NSAID-induced gastric injury, acetic acid colitis, and intestinal anastomosis. Proposed mechanisms include upregulation of growth factors (EGF, bFGF), stimulation of angiogenesis through VEGFR2 signaling, and modulation of the nitric oxide (NO) system. The cytoprotective effects appear to extend beyond the stomach to the entire GI tract, including esophagus, small intestine, and colon (Sikiric P et al., Curr Pharm Des, 2018).

Intestinal anastomosis healing: One of the more surgically relevant research applications of BPC-157 is its ability to accelerate anastomotic healing — reducing the risk of anastomotic leakage in intestinal surgery models. Studies in rat models have shown consistently improved anastomotic bursting pressures and reduced fistula formation.

Inflammatory bowel disease models: In acetic acid and TNBS-induced colitis models (common preclinical IBD research models), BPC-157 administration significantly reduced macroscopic damage scores, mucosal inflammatory cytokines, and histological injury markers. These effects have been reproduced by multiple independent laboratories.

Systemic and gut-brain axis effects: BPC-157 also demonstrates effects on the enteric nervous system, modulating dopaminergic and serotonergic pathways relevant to gut motility and the gut-brain axis. Research by Sikiric's group has documented BPC-157's ability to counteract dopamine agonist/antagonist-induced dyskinesias in animal models, suggesting central nervous system interaction.

Research parameters: Most preclinical studies use 10 ng/kg to 10 mcg/kg by various routes (subcutaneous, oral, intraperitoneal, intragastric). Oral BPC-157 appears to retain biological activity, which is unusual for peptides and may be due to its gastric juice origin and stability in acidic environments.

See full research profile: BPC-157

---

KPV (Lys-Pro-Val — α-MSH Tripeptide)

Molecular weight: 340.4 Da

Structure: Lys-Pro-Val (C-terminal tripeptide of alpha-melanocyte stimulating hormone)

Primary transporter: PepT1 (SLC15A1) oligopeptide transporter

KPV is derived from the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH), which itself is a potent endogenous anti-inflammatory peptide. KPV retains the anti-inflammatory activity of α-MSH but in a form small enough to be transported directly into intestinal epithelial cells via the PepT1 di/tripeptide transporter:

PepT1-mediated cellular entry: Unlike most anti-inflammatory agents that act on cell surface receptors, KPV is actively transported into intestinal epithelial cells by PepT1 — an oligopeptide transporter expressed at high levels in the brush border of the small intestine and throughout the colon. This intracellular uptake enables direct suppression of NF-κB signaling from within the epithelial cell, targeting the central pro-inflammatory transcription factor driving chronic gut inflammation.

NF-κB pathway suppression: Intracellular KPV inhibits IκB kinase (IKK) phosphorylation, preventing IκB degradation and subsequent nuclear translocation of NF-κB. The net effect is reduced transcription of TNF-α, IL-6, IL-8, and other pro-inflammatory cytokines in intestinal epithelial cells. Research by Dalmasso et al. demonstrated that KPV dose-dependently inhibited pro-inflammatory cytokine secretion from colonocytes under inflammatory challenge conditions.

Colitis research: In mouse models of TNBS-induced colitis, KPV administration (oral and systemic) significantly reduced histological damage scores, neutrophil infiltration, and mucosal cytokine levels. The oral route appears particularly relevant given PepT1's brush border localization — oral KPV is delivered directly to the site of pathology in colitis models.

Combination with BPC-157: KPV and BPC-157 are mechanistically complementary: BPC-157 drives healing and angiogenesis from the submucosal level up, while KPV suppresses the epithelial-level inflammatory signaling that would otherwise impair healing. This makes the KPV + BPC-157 combination particularly well-suited for inflammatory GI research models.

Research parameters: Preclinical studies have used doses ranging from 10 mcg/kg to 1 mg/kg; oral and systemic routes both appear active.

See full research profile: KPV

---

Larazotide Acetate (AT-1001)

Molecular weight: 843.9 Da

Mechanism class: Zonulin antagonist / tight junction regulator

Development status: Phase III clinical trials completed (celiac disease)

Larazotide acetate (also known as AT-1001) is an 8-amino-acid synthetic peptide developed as a first-in-class zonulin antagonist. Zonulin is the human analogue of Zot (zonula occludens toxin) produced by Vibrio cholerae, and endogenous zonulin regulates tight junction permeability in the gut:

Tight junction biology: The intestinal epithelium is sealed by tight junctions — protein complexes containing claudins, occludin, and zonula occludens proteins (ZO-1, ZO-2) — that control paracellular flux. Zonulin binds to chemokine receptor 3 (CXCR3) on epithelial cells, triggering internalization of ZO-1 and opening of tight junctions. In inflammatory bowel disease, celiac disease, and other conditions associated with "leaky gut," zonulin is chronically elevated.

Mechanism of larazotide: Larazotide acetate acts as a competitive antagonist at CXCR3, blocking zonulin-induced tight junction opening. In research models, larazotide reduces paracellular flux markers (lactulose/mannitol ratio), stabilizes ZO-1 membrane localization, and reduces translocation of luminal antigens into systemic circulation.

Clinical trial data: Larazotide acetate has undergone multiple Phase II and Phase III clinical trials in celiac disease. The pivotal study by Leffler et al. (JAMA, 2015,) demonstrated that larazotide acetate 0.5 mg three times daily significantly reduced gastrointestinal symptom severity in celiac patients maintained on a gluten-free diet compared to placebo. While the primary endpoint for intestinal permeability showed a trend, symptom improvement was statistically significant — suggesting clinically relevant tight junction effects even when assessed indirectly.

Research applications: Beyond celiac disease, larazotide acetate is being studied in IBD, irritable bowel syndrome, diabetes (gut permeability in metabolic disease), and even neurological conditions where gut permeability may influence systemic inflammation.

Research parameters: Clinical doses have ranged from 0.25 mg to 4 mg orally three times daily. Oral bioavailability is intentionally limited — the compound is designed to act locally in the gut lumen.

See full research profile: Larazotide Acetate

---

Pentadecarginate (PDA)

Molecular weight: ~1,800 Da

Structure: 15-amino acid arginine-rich peptide

Proposed mechanisms: Arginine-based NO regulation, membrane stabilization, structural scaffold support

Pentadecarginate (PDA) is a synthetic peptide that has emerged more recently in research compared to BPC-157 and KPV. It represents a structurally distinct approach to GI repair — one focused on providing the building blocks and signaling environment for physical tissue reconstruction:

Arginine and nitric oxide signaling: PDA's arginine content provides substrate for nitric oxide synthase (NOS) activity in gut tissue. NO plays complex roles in GI biology: at physiological levels, it supports gut barrier function (PMID: 39397201), mucosal blood flow, coordinates intestinal smooth muscle relaxation, and promotes epithelial healing. Research on PDA suggests it may modulate local NO levels in gut tissue in ways that support healing without triggering the excessive NO production seen in severe inflammation.

Mucosal structural support: Early PDA research (2022–2023) has examined its effects on mucosal integrity in models of NSAID-induced gut damage and alcohol-induced mucosal injury, with findings suggesting improved structural markers of the intestinal wall including reduced myeloperoxidase activity (a neutrophil infiltration marker) and improved crypt/villus architecture scores.

Complementarity with BPC-157: PDA and BPC-157 are frequently studied as a pair because they appear to address different phases of mucosal healing. BPC-157 excels at initiating the healing cascade and promoting angiogenesis in early repair phases, while PDA may support later-phase structural consolidation. Research comparing BPC-157 and PDA head-to-head suggests partially overlapping but distinct mechanisms (see our BPC-157 vs PDA comparison).

Research parameters: Preliminary research has used a range of doses; standardized research protocols are still being established. Oral and subcutaneous routes have both been studied.

Stack Protocol

Dosing Windows & Sequencing

The sequencing logic for this stack follows the logical order of gut repair mechanisms:

Larazotide (taken with meals — 3× daily):

• •Oral administration timed with meals to maximize exposure during active dietary antigen challenge
• •As a luminal-acting agent, larazotide works best when the gut is processing food and tight junctions are most challenged

KPV (between meals — 2–3× daily):

• •Oral KPV taken between meals to maximize PepT1-mediated uptake without competition from dietary di/tripeptides (which also use PepT1)
• •Anti-inflammatory effect is continuous rather than meal-dependent

BPC-157 (morning and/or evening — subcutaneous or oral):

• •Subcutaneous: 1–2 injections daily (research protocols)
• •Oral: split dose with water, away from food (research protocols suggest oral activity in animal models)
• •Timing is flexible relative to meals for the subcutaneous route

Pentadecarginate (evening — subcutaneous):

• •Evening administration to align with the rest-and-repair phase of the circadian cycle
• •Gut epithelial cell turnover is highest during sleep; tissue repair processes are more active in this phase

Reconstitution Notes

BPC-157:

• •Reconstitute with bacteriostatic water to 0.5–1 mg/mL
• •Swirl gently; store at 4°C; use within 4 weeks
• •For oral research use: some protocols use sterile saline mixed with water as the vehicle

KPV:

• •Typically supplied as lyophilized powder
• •Reconstitute with sterile water or saline for injection; for oral use, can be dissolved in water
• •Store reconstituted at 4°C; use within 3 weeks

Larazotide Acetate:

• •Available in research-grade oral capsule or powder form
• •For research protocols mimicking clinical trials, oral administration with water 30 min before meals is standard

Pentadecarginate:

• •Reconstitute lyophilized powder with sterile BAC water to 1–5 mg/mL
• •Store at 4°C; minimize freeze-thaw cycles; lyophilized stable at -20°C

Storage Summary

Research Evidence Summary

The evidence base for this stack varies by compound:

• •BPC-157: The most studied compound in this stack, with 30+ years of preclinical research and multiple independent laboratories confirming mucosal protective effects across GI pathology models.
• •KPV: Strong preclinical data on NF-κB suppression via PepT1; mechanism-of-action is well-established. Human trial data is limited.
• •Larazotide: The strongest clinical evidence in this stack — Phase III trial data in celiac disease provides human-level validation of the tight junction mechanism.
• •Pentadecarginate: Newest and least-studied compound; preliminary research is promising but requires replication.

No published study has examined this four-compound combination as a complete stack. The mechanistic rationale for combination is well-grounded in the complementarity of mechanisms.

Frequently Asked Questions

Q: Can BPC-157 and KPV be taken at the same time?

A: In preclinical research, these compounds have been studied both individually and in combination. They act through different mechanisms and different cellular targets, so coadministration is not expected to cause interference. However, formal combination pharmacokinetic studies have not been published.

Q: Is oral BPC-157 as effective as subcutaneous in gut research?

A: In animal studies, oral BPC-157 has demonstrated biological activity, which is unusual for peptides given typical gastrointestinal degradation. Sikiric's group has published data supporting oral efficacy specifically in GI models, though the systemic bioavailability of oral BPC-157 remains debated. For systemic effects, subcutaneous is generally preferred in research protocols.

Q: What is the difference between larazotide and BPC-157 for gut permeability?

A: They act at different levels. Larazotide blocks zonulin from opening tight junctions — it's a preventive or containment mechanism at the paracellular seal. BPC-157 drives mucosal healing at the cellular and tissue level through growth factor and angiogenic mechanisms. Both are relevant to gut permeability, but through different mechanisms.

Q: Is pentadecarginate different from BPC-157?

A: Yes. Despite some surface similarities (both are synthetic peptides studied for GI repair), PDA and BPC-157 have different structures, different mechanisms, and different published literature. They appear complementary rather than redundant. See our detailed comparison.

Where to Source These Peptides

Compare verified suppliers for each compound in this stack:

• •Compare BPC-157 suppliers
• •Compare KPV suppliers
• •Compare Larazotide suppliers
• •Compare Pentadecarginate/PDA suppliers

For research purposes only. Verify compound purity via third-party Certificate of Analysis before any research use.